GlassScriptPhysician profile
Ramprasad Subramaniam
NPI 1932128998
$2,965.10
in general payments reported to CMS, 2019-2025
21 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $278 · 2021: $319 · 2022: $378 · 2023: $376 · 2024: $489 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $866.77 | 2019-2024 | Xarelto |
| Pfizer INC. | $625.23 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $395.04 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $180.43 | 2019-2022 | |
| Ucb, INC. | $149.51 | 2021-2024 | Briviact |
| Merck Sharp & Dohme LLC | $114.13 | 2019-2024 | Verquvo, Dificid |
| Inari Medical, INC. | $106.33 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $99.71 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.48 | 2021-2023 | Jardiance |
| Mallinckrodt Hospital Products INC. | $59.22 | 2025 | Terlivaz |
| Novo Nordisk INC | $52.42 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.46 | 2020-2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $48.31 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $34.98 | 2019 | |
| Melinta Therapeutics, LLC | $33.13 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $19.35 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $19.13 | 2022 | |
| Stryker Corporation | $18.71 | 2025 | Ivas |
| Otsuka America Pharmaceutical, INC. | $18.01 | 2019 | |
| Allergan, INC. | $14.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramprasad Subramaniam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.